



Press release

Intended for international media and investor audiences only



Annual General Meeting of Ipsen S.A. of 28 May 2024

» Voting results

PARIS, FRANCE, 28 May 2024

Number of shares comprising the capital	83,814,526
Number of shares with voting rights	82,710,897
Number of shareholders present, represented or voting by mail	2,804
Number of shares held by shareholders present, represented or voting by mail	68,895,080
Number of votes held by shareholders present, represented or voting by mail	116,829,859
Quorum	83.30%

Resolutions	Total number of votes cast	Number of shares	% of capital cast	Votes for		Votes against		Votes not validly cast			Result
				Number	%	Number	%	Abstention	Void	Not voted	
As an Ordinary Annual General Meeting											
1. Approval of the annual financial statements for the financial year ending 31 December 2023	116,717,046	68,895,080	82.07	116,687,633	99.97	29,413	0.03	112,435	0	378	Adopted
2. Approval of the consolidated financial statements for the financial year ending 31 December 2023	116,717,395	68,895,080	82.07	116,687,982	99.97	29,413	0.03	112,435	0	29	Adopted
3. Allocation of the results for the 2023 financial year and setting of the dividend at €1.20 per share	116,825,331	68,895,080	82.19	116,791,703	99.97	33,628	0.03	4,499	0	29	Adopted
4. Special report of the Statutory Auditors on regulated agreements – Finding of absence of new agreement	116,828,466	68,895,080	82.20	116,828,188	>99.99	278	<0.01	1,364	0	29	Adopted
5. Appointment of PricewaterhouseCoopers Audit, as statutory auditor, in charge of the certification of sustainability information	116,789,372	68,895,080	82.15	116,735,073	99.95	54,299	0,05	40,458	0	29	Adopted
6. Renewal of the term of office of BEECH TREE S.A. as a Director	116,781,989	68,895,080	82.14	101,830,481	87.20	14,951,508	12.80	47,841	0	29	Adopted
7. Renewal of the term of office of Mrs. Carol XUEREF as a Director	116,823,252	68,895,080	82.19	99,982,528	85.58	16,840,724	14.42	6,558	0	49	Adopted
8. Ratification of the temporary appointment of Mr. Pascal TOUCHON as a Director	116,820,529	68,895,080	82.19	116,606,016	99.82	214,513	0.18	9,301	0	29	Adopted
9. Approval of the compensation policy applicable to the members of the Board of Directors	116,823,387	68,895,080	82.19	116,789,239	99.97	34,148	0.03	6,443	0	29	Adopted
10. Approval of the compensation policy applicable to the Chairman of the Board of Directors	116,823,228	68,895,080	82.19	116,660,190	99.86	163,038	0.14	6,582	0	49	Adopted

Resolutions	Total number of votes cast	Number of shares	% of capital cast	Votes for		Votes against		Votes not validly cast			Result
				Number	%	Number	%	Abstention	Void	Not voted	
11. Approval of the compensation policy applicable to the Chief Executive Officer and/or any other executive officer	116,723,878	68,895,080	82.07	110,838,381	94.96	5,885,497	5.04	105,952	0	29	Adopted
12. Approval of the information notably relating to the compensation of corporate officers referred to in I of Article L.22-10-9 of the French Commercial Code	116,819,457	68,895,080	82.19	115,161,917	98.58	1,657,540	1.42	10,353	0	49	Adopted
13. Approval of the base, variable and exceptional elements making up the total compensation and the benefits of any kind paid during the past financial year or granted for the same financial year to Mr. Marc de GARIDEL, Chairman of the Board of Directors	116,820,437	68,895,080	82.19	116,643,306	99.85	177,131	0.15	9,393	0	29	Adopted
14. Approval of the base, variable and exceptional elements making up the total compensation and the benefits of any kind paid during the past financial year or granted for the same financial year to Mr. David LOEW, Chief Executive Officer	116,605,211	68,895,080	81.93	113,954,361	97.73	2,650,850	2.27	224,619	0	29	Adopted
15. Authorization to be given to the Board of Directors to allow the company to repurchase its own shares pursuant to the provisions of article L.22-10-62 of the French Commercial Code, duration of the authorization, purposes, terms, ceiling, suspension during a public offering period	116,814,133	68,895,080	82.18	116,757,622	99.95	56,511	0.05	15,697	0	29	Adopted

As an Extraordinary Annual General Meeting											
16. Authorization to be given to the Board of Directors to carry out free grants of shares to salaried staff members and/or certain corporate officers of the company or affiliated companies or economic interest groups, waiver by shareholders of their preferential subscription rights, duration of the authorization, ceiling, duration of the vesting period, notably in the event of disability and, where applicable, retention period	116,824,887	68,895,080	82.19	101,067,377	86.51	15,757,510	13.49	4,943	0	29	Adopted
As an Ordinary Annual General Meeting											
17. Powers to carry out formalities	116,815,071	68,895,080	82.18	116,814,716	>99.99	355	<0.01	14,639	0	149	Adopted

ENDS

About Ipsen

We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.

Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries.

Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipсен.com.

Ipsen contacts

Investors

Craig Marks | + 44 (0) 7584 349 193

Nicolas Bogler | + 33 (0) 6 52 19 98 92

Media

Amy Wolf | + 41 (0) 79 576 07 23

Ioana Piscociu | + 33 (0) 6 69 09 12 96

Disclaimers and/or Forward-Looking Statements

The forward-looking statements, objectives and targets contained herein are based on Ipsen's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including Ipsen's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen's patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen's activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen's partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen's business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this

press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen's latest Universal Registration Document, available on ipсен.com.